- $849.87m
- $760.36m
- $14.08m
Brief: Arbutus Provides 2025 Corporate And Financial Update
U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart
Brief: Arbutus & Barinthus Bio Announce New Data From The IM-PROVE II Trial
Brief: Arbutus Biopharma files for mixed shelf of up to $300 mln
Arbutus Biopharma Corp expected to post a loss of 9 cents a share - Earnings Preview
Brief: Arbutus To Report Third Quarter 2024 Financial Results And Provide Corporate Update
Brief: Arbutus Biopharma Says Co, Moderna, Others Filed Stipulation To Extend Time With US District Court In Lawsuit
Arbutus Biopharma Corp reports results for the quarter ended in June - Earnings Summary
Brief: Arbutus Biopharma Q2 Revenue USD 1.7 Million Vs. IBES Estimate USD 1.75 Million
Arbutus Biopharma Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Morgan Stanley Reports 10.3% Passive Stake In Arbutus Biopharma Corp As Of May 31- SEC Filing
Brief: Arbutus Says Imdusiran With Short Course Interferon Achieves Sustained Undetectable HBsAg, A Necessity For HBV Functional Cure
U.S. STOCKS ON THE MOVE-Cracker Barrel, Robinhood Markets, DuPont
U.S. STOCKS ON THE MOVE-Tilray Brands, Arbutus Biopharma, Coinbase
Arbutus up after investor Whitefort urges co to stop share sales, find partner
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner (updated)
Brief: Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner
Brief: Arbutus Biopharma Q1 Revenue USD 1.5 Million